Cardiometabolic & Chronic Care

Why it matters

Cardiovascular diseases are the leading cause of death globally — about 19.8 million deaths in 2022, with more than 75% in low- and middle-income countries — and the number of people living with diabetes rose from 200 million in 1990 to 830 million in 2022, fastest in LMICs (WHO, 2025; WHO, 2024). The control gap is stark: of the roughly 1.4 billion adults aged 30–79 with hypertension, two-thirds live in LMICs, about 46% are unaware they have it, and only around 21% have it controlled (WHO, 2025). Standardized programmes close that gap cost-effectively — through the Global Hearts Initiative, more than 13.5 million people across 40-plus LMICs have been put on protocol-based hypertension treatment (WHO, 2025).

InBasket AI keeps chronic cardiometabolic care on one continuous record so a small care team can work from a single, trustworthy source of truth — part of expanding access to care for the next billion people.

Designed with reference to recognized global, national, and clinical standards

This care area is designed with reference to a standards ecosystem, including global guidance, national protocols, specialty-society recommendations, interoperability standards, and programme reporting requirements where applicable:

• WHO HEARTS technical package and Package of Essential NCD (PEN) interventions
• KDIGO CKD staging and renal-risk medication-safety guidance
• International Diabetes Federation / ADA Standards of Care diabetes-management principles where locally adopted
• ACC/AHA, ESC, or national cardiovascular-risk and hypertension guidance where locally adopted
• National Ministry of Health standard treatment guidelines, essential medicines lists, and local scope-of-practice rules for the implementation setting
• HL7 FHIR, ICD-10, LOINC, SNOMED CT, and local terminology/coding standards where adopted

Standards sources

These sources substantiate the standards named above. Implementation-specific national protocols are selected from official national or regional authorities during deployment.

1. [1]World Health Organization guidelines and publications
2. [2]KDIGO guidelines
3. [3]Official national Ministry of Health protocols for the implementation setting — Implementation-specific: selected from the official national or regional authority during deployment.
4. [4]American Diabetes Association Standards of Care
5. [5]ACC/AHA clinical guidance
6. [6]European Society of Cardiology guidelines
7. [7]HL7 FHIR
8. [8]WHO ICD classifications
9. [9]LOINC
10. [10]SNOMED CT

Evidence sources

• WHO Cardiovascular diseases (2025)
• ·WHO Diabetes (2024)
• ·WHO Hypertension (2025)